A5091576909- Parathyroid Disorders and Treatments
- Dialysis and Renal Disease Management
- Magnesium in Health and Disease
- Vitamin D Research Studies
- Pharmacological Effects and Toxicity Studies
- Erythropoietin and Anemia Treatment
- Neurological and metabolic disorders
- Genetic Syndromes and Imprinting
- Bone health and treatments
- Diet and metabolism studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hemoglobinopathies and Related Disorders
- Medical Imaging and Pathology Studies
- Sodium Intake and Health
- Renal function and acid-base balance
- Electrolyte and hormonal disorders
- Aluminum toxicity and tolerance in plants and animals
- Thyroid and Parathyroid Surgery
- Iron Metabolism and Disorders
- Trace Elements in Health
- Metabolism and Genetic Disorders
- Chronic Kidney Disease and Diabetes
- Blood Pressure and Hypertension Studies
- Ion Transport and Channel Regulation
- Erythrocyte Function and Pathophysiology
Hôpital Paul-Brousse
2016-2025
Inserm
2016-2025
Université Paris-Saclay
2016-2025
Université Paris-Sud
2016-2025
Université de Versailles Saint-Quentin-en-Yvelines
2016-2025
Centre de recherche en Epidémiologie et Santé des Populations
2016-2025
Centre de Recherche des Cordeliers
2025
RELX Group (United States)
2016-2023
Conference Board
2023
Center for Translational Molecular Medicine
2016-2021
Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established.
Treatment of secondary hyperparathyroidism with vitamin D and calcium in patients receiving dialysis is often complicated by hypercalcemia hyperphosphatemia, which may contribute to cardiovascular disease adverse clinical outcomes. Calcimimetics target the calcium-sensing receptor lower parathyroid hormone levels without increasing phosphorus levels. We report results two identical randomized, double-blind, placebo-controlled trials evaluating safety effectiveness calcimimetic agent...
Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute extraskeletal (including vascular) calcification among patients with chronic kidney disease. It has been hypothesized that treatment the calcimimetic agent cinacalcet might reduce risk death or nonfatal cardiovascular events in such patients.In this clinical trial, we randomly assigned 3883 moderate-to-severe hyperparathyroidism (median level intact parathyroid hormone, 693 pg per milliliter...
We previously demonstrated the presence of advanced oxidation protein products (AOPP), a novel marker oxidative stress in plasma uremic patients receiving maintenance dialysis. The present study cohort 162 showed that concentrations AOPP increased with progression chronic renal failure and were closely related to glycation end (AGE)-pentosidine (r = 0.52, p < 0.001), taken as AGE. In vivo, relevance AGE-pentosidine monocyte-mediated inflammatory syndrome associated uremia was evidenced by...
A number of US observational studies reported an increased mortality risk with higher intact parathyroid hormone (iPTH), calcium and/or phosphate. The existence such a link in European haemodialysis population was explored as part the Analysing Data, Recognising Excellence and Optimising Outcomes (ARO) Chronic Kidney Disease (CKD) Research Initiative.The association between markers mineral bone disease clinical outcomes examined 7970 patients treated Fresenius Medical Care facilities over...
The pathogeneses of parathyroid disease in patients with uremia and nonfamilial primary hyperplasia are poorly understood. Because multigland involvement, it has been assumed that these common diseases predominantly involve polyclonal (non-neoplastic) cellular proliferations, but an overall assessment their clonality not done. We examined the hyperplastic tumors using X-chromosome inactivation analysis M27 beta (DXS255) DNA polymorphism by searching for monoclonal allelic losses at loci on...
Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These are associated cardiovascular all-cause mortality. The objective was to determine the effects calcimimetic cinacalcet (versus placebo) on reducing FGF23 whether changes in death events.This a secondary analysis randomized clinical trial comparing placebo addition conventional therapy (phosphate binders/vitamin D) patients receiving...
<h3>Importance</h3> Secondary hyperparathyroidism contributes to extraskeletal calcification and is associated with all-cause cardiovascular mortality. Control suboptimal in the majority of patients receiving hemodialysis. An intravenously (IV) administered calcimimetic could improve adherence reduce adverse gastrointestinal effects. <h3>Objective</h3> To evaluate relative efficacy safety IV etelcalcetide oral cinacalcet. <h3>Design, Setting, Participants</h3> A randomized, double-blind,...
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent associated with significant adverse consequences. 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an guideline for managing the diagnosis, evaluation, treatment of in disease. Since then, new data have accrued from basic research, epidemiological studies, randomized trials that warrant a re-examination previous recommendations. Therefore, 2019, KDIGO decided to convene 2 Controversies Conferences...
Background— Increased common carotid artery intima-media thickness (CCA-IMT) is a marker of early atherosclerosis. Low-grade inflammation associated with the pathogenesis and increased CCA-IMT are observed in end-stage renal disease (ESRD). Oxidative stress involved uremia-related inflammation. Advanced oxidation protein products (AOPP) markers oxidant-mediated damage ESRD. Intravenous iron given to patients on hemodialysis (HD) might induce oxidative stress. We investigated relationships...
Abstract Spinal radiologic lesions suggestive of destructive spondylarthropathy were found in 10 patients on long‐term hemodialysis. These characterized by severe narrowing the intervertebral disc, associated with erosions and geodes adjacent vertebral plates without osteophytosis. In 9 located cervical spine, 1 patient, lumbar spine. Microbial spondylitis, degenerative disc disease, calcium pyrophosphate dihydrate deposition disease each, turn, ruled out. The finding apatite crystals...
Background. Malnutrition is common in dialysis patients and closely related to morbidity mortality. Therefore, assessment of nutritional status management play a central role everyday nephrological practice.
Background. Oxidative stress has long been demonstrated in haemodialysis patients. However, the factors influencing their oxidative status have not characterized extensively these Therefore, present study was designed to investigate influence of a large number known be associated with stress.